Mavyret — Net revenues
AbbVie Mavyret — Net revenues increased by 8.3% to $351M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 14.7%, from $306M to $351M. Over 4 years (FY 2021 to FY 2025), Mavyret — Net revenues shows a downward trend with a -6.3% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase suggests sustained market share or successful patient access strategies, while a decrease indicates potential market saturation, generic competition, or a shift in the standard of care.
Detailed definition
This metric represents the total net sales generated from the specific pharmaceutical product line used for the treatmen...
Peer comparison
Comparable to specific therapeutic product revenue lines reported by other large-cap pharmaceutical companies, often evaluated against the backdrop of patent cliffs and competitive entry.
abbv_segment_mavyret_net_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $442M | $426M | $427M | $380M | $398M | $383M | $380M | $364M | $387M | $370M | $309M | $349M | $369M | $302M | $291M | $306M | $375M | $312M | $324M | $351M |
| QoQ Change | — | -3.6% | +0.2% | -11.0% | +4.7% | -3.8% | -0.8% | -4.2% | +6.3% | -4.4% | -16.5% | +12.9% | +5.7% | -18.2% | -3.6% | +5.2% | +22.5% | -16.8% | +3.8% | +8.3% |
| YoY Change | — | — | — | — | -10.0% | -10.1% | -11.0% | -4.2% | -2.8% | -3.4% | -18.7% | -4.1% | -4.7% | -18.4% | -5.8% | -12.3% | +1.6% | +3.3% | +11.3% | +14.7% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is AbbVie's mavyret — net revenues?
- AbbVie (ABBV) reported mavyret — net revenues of $351M in Q1 2026.
- How has AbbVie's mavyret — net revenues changed year-over-year?
- AbbVie's mavyret — net revenues increased by 14.7% year-over-year, from $306M to $351M.
- What is the long-term trend for AbbVie's mavyret — net revenues?
- Over 4 years (2021 to 2025), AbbVie's mavyret — net revenues has grown at a -6.3% compound annual growth rate (CAGR), from $1.71B to $1.32B.
- What does mavyret — net revenues mean?
- The total revenue generated from sales of the company's hepatitis C treatment product.